170 related articles for article (PubMed ID: 17472358)
21. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
22. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
Qiu Q; Dudouit F; Matheson SL; Brahimi F; Banerjee R; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):1-10. PubMed ID: 12497200
[TBL] [Abstract][Full Text] [Related]
23. Triazenoindazoles and triazenopyrazolopyridines: design, synthesis, and cytotoxic activity.
Abdel-Hakeem M
Arch Pharm Res; 2010 Jun; 33(6):813-9. PubMed ID: 20607485
[TBL] [Abstract][Full Text] [Related]
24. Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile.
Huang Y; Rachid Z; Peyrard L; Senhaji Mouhri Z; Williams C; Jean-Claude BJ
Chem Biol Drug Des; 2015 Feb; 85(2):153-62. PubMed ID: 25092264
[TBL] [Abstract][Full Text] [Related]
25. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
Heravi M; Rachid Z; Goudarzi A; Schlisser A; Jean-Claude BJ; Radzioch D; Muanza TM
Anticancer Drugs; 2009 Sep; 20(8):659-67. PubMed ID: 19581798
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
[TBL] [Abstract][Full Text] [Related]
27. The 5'-GNC preference for mustard cross-linking is preserved in a restriction fragment.
Millard JT; Luedtke NW; Spencer RJ
Anticancer Drug Des; 1996 Sep; 11(6):485-92. PubMed ID: 8836112
[No Abstract] [Full Text] [Related]
28. The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
Banerjee R; Huang Y; Qiu Q; McNamee JP; Belinsky G; Jean-Claude BJ
Cell Signal; 2011 Apr; 23(4):630-40. PubMed ID: 21138763
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase.
Larroque AL; Peori B; Williams C; Fang YQ; Qiu Q; Rachid Z; Jean-Claude BJ
Chem Biol Drug Des; 2008 Apr; 71(4):374-9. PubMed ID: 18324926
[TBL] [Abstract][Full Text] [Related]
30. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK.
Larroque-Lombard AL; Todorova M; Qiyu Q; Jean-Claude B
Chem Biol Drug Des; 2011 May; 77(5):309-18. PubMed ID: 21294849
[TBL] [Abstract][Full Text] [Related]
32. BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
Doria F; Richter SN; Nadai M; Colloredo-Mels S; Mella M; Palumbo M; Freccero M
J Med Chem; 2007 Dec; 50(26):6570-9. PubMed ID: 18047263
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of new bifunctional compounds which selectively alkylate guanines in DNA.
Henderson ND; Lacy SM; O'Hare CC; Hartley JA; McClean S; Wakelin LP; Kelland LR; Robins DJ
Anticancer Drug Des; 1998 Oct; 13(7):749-68. PubMed ID: 9807160
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.
MacPhee M; Rachid Z; Todorova M; Qiu Q; Belinsky G; Jean-Claude BJ
Invest New Drugs; 2011 Oct; 29(5):833-45. PubMed ID: 20428924
[TBL] [Abstract][Full Text] [Related]
35. Adenine-containing DNA-DNA cross-links of antitumor nitrogen mustards.
Balcome S; Park S; Quirk Dorr DR; Hafner L; Phillips L; Tretyakova N
Chem Res Toxicol; 2004 Jul; 17(7):950-62. PubMed ID: 15257621
[TBL] [Abstract][Full Text] [Related]
36. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
Matheson SL; Brahimi F; Jean-Claude BJ
Biochem Pharmacol; 2004 Mar; 67(6):1131-8. PubMed ID: 15006549
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.
Pors K; Paniwnyk Z; Ruparelia KC; Teesdale-Spittle PH; Hartley JA; Kelland LR; Patterson LH
J Med Chem; 2004 Mar; 47(7):1856-9. PubMed ID: 15027879
[TBL] [Abstract][Full Text] [Related]
38. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
39. Mitomycin dimers: polyfunctional cross-linkers of DNA.
Paz MM; Kumar GS; Glover M; Waring MJ; Tomasz M
J Med Chem; 2004 Jun; 47(12):3308-19. PubMed ID: 15163210
[TBL] [Abstract][Full Text] [Related]
40. [Synthesis and antitumor activity of benzoic nitrogen mustard derivatives].
Luo W; Zhao YM; Wang YX; Xie SQ; Zhao J; Wang CJ
Yao Xue Xue Bao; 2007 Dec; 42(12):1327-9. PubMed ID: 18338650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
